A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncol... von Cherny, N.I., Sullivan, R., Dafni, U., Kerst, J.M., Sobrero, A., Zielinski, C., de Vries, E.G.E., Piccart, M.J.

Volltext

ESMO-Magnitude of Clinical Benefit Scale version 1.1 von Cherny, N.I., Dafni, U., Bogaerts, J., Latino, N.J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M.J., de Vries, E.G.E.

Volltext

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate von Garassino, M.C., Vyas, M., de Vries, E.G.E., Kanesvaran, R., Giuliani, R., Peters, S.

Volltext

Rectal and colon cancer: Not just a different anatomic site von Tamas, K, Walenkamp, A.M.E, de Vries, E.G.E, van Vugt, M.A.T.M, Beets-Tan, R.G, van Etten, B, de Groot, D.J.A, Hospers, G.A.P

Volltext

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR tria... von Gebhart, G., Lamberts, L.E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W.J.G., Vugts, D.J., Hoekstra, O.S., Schröder, C.P., Menke-van der Houven van Oordt, C.W., Guiot, T., Brouwers, A.H., Awada, A., de Vries, E.G.E., Flamen, P.

Volltext

ATR inhibition preferentially targets homologous recombination-deficient tumor cells von Krajewska, M, Fehrmann, R S N, Schoonen, P M, Labib, S, de Vries, E G E, Franke, L, van Vugt, M A T M

Volltext

The antibody–drug conjugate target landscape across a broad range of tumour types von Moek, K.L., de Groot, D.J.A., de Vries, E.G.E., Fehrmann, R.S.N.

Volltext

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit von Oosting, S.F., Barriuso, J., Bottomley, A., Galotti, M., Gyawali, B., Kiesewetter, B., Latino, N.J., Martinelli, F., Pe, M., Pentheroudakis, G., Roitberg, F., Vachon, H., de Vries, E.G.E., Piccart, M., Cherny, N.I.

Volltext

Prognostic versus predictive value of biomarkers in oncology von Oldenhuis, C.N.A.M, Oosting, S.F, Gietema, J.A, de Vries, E.G.E

Volltext

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients von Vollebergh, M.A., Lips, E.H., Nederlof, P.M., Wessels, L.F.A., Schmidt, M.K., van Beers, E.H., Cornelissen, S., Holtkamp, M., Froklage, F.E., de Vries, E.G.E., Schrama, J.G., Wesseling, J., van de Vijver, M.J., van Tinteren, H., de Bruin, M., Hauptmann, M., Rodenhuis, S., Linn, S.C.

Volltext

When is off-label off-road? von de Vries, E.G.E., Cherny, N.I., Voest, E.E.

Volltext

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination von Krajewska, M, Heijink, A M, Bisselink, Y J W M, Seinstra, R I, Silljé, H H W, de Vries, E G E, van Vugt, M A T M

Volltext

Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors von Boer, H., Proost, J.H., Nuver, J., Bunskoek, S., Gietema, J.Q., Geubels, B.M., Altena, R., Zwart, N., Oosting, S.F., Vonk, J.M., Lefrandt, J.D., Uges, D.R.A., Meijer, C., de Vries, E.G.E., Gietema, J.A.

Volltext

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0 von Kiesewetter, B., Dafni, U., de Vries, E.G.E., Barriuso, J., Curigliano, G., González-Calle, V., Galotti, M., Gyawali, B., Huntly, B.J.P., Jäger, U., Latino, N.J., Malcovati, L., Oosting, S.F., Ossenkoppele, G., Piccart, M., Raderer, M., Scarfò, L., Trapani, D., Zielinski, C.C., Wester, R., Zygoura, P., Macintyre, E., Cherny, N.I.

Volltext

Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect von Ariaans, G, de Jong, S, Gietema, J.A, Lefrandt, J.D, de Vries, E.G.E, Jalving, M

Volltext

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer von van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W.

Volltext

Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial von de Hosson, L D, Bouma, G, Stelwagen, J, van Essen, H, de Bock, G H, de Groot, D J A, de Vries, E G E, Walenkamp, A M E

Volltext

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring von Gyawali, B., de Vries, E.G.E., Dafni, U., Amaral, T., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez-Roca, C., Kiesewetter, B., Oosting, S., Passaro, A., Pentheroudakis, G., Piccart, M., Roitberg, F., Tabernero, J., Tarazona, N., Trapani, D., Wester, R., Zarkavelis, G., Zielinski, C., Zygoura, P., Cherny, N.I.

Volltext

Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic von de Groot, D.J.A, de Vries, E.G.E, Groen, H.J.M, de Jong, S

Volltext

Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET von Antunes, I. F., Hospers, G. A. P., Sijbesma, J. W. A., Boerema, A. S., van Waarde, A., Glaudemans, A. W. J. M, Dierckx, R. A. J. O., de Vries, E. G. E., de Vries, E. F. J.

Volltext